Novel cancer research behind Belgian biotech Montis

20 February 2020
belgium-big

A new Belgian biotech, Montis Biosciences, has launched with 8.4 million euros ($9 million) in seed financing.

Investors including Polaris Partners, ALSA Ventures and Pfizer Ventures, the venture capital arm of Pfizer (NYSE: PFE), are backing the company.

Montis has been spun out from VIB-KU Leuven, a life sciences research group, drawing from foundational science conducted at the Flanders-based institute.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology